Palonosetron Hydrochloride
|
|
|
- CAS-Nr.
- 135729-62-3
- Englisch Name:
- Palonosetron Hydrochloride
- Synonyma:
- PALONOSETRON HCL;Aloxi;Palonosetron HCI;CS-292;Onicit;RS 25259;RS-25259-197;PalnosetronHcl;a 5-HT3 antagonist;Palonosetron-d3 HCl
- CBNumber:
- CB0210849
- Summenformel:
- C19H25ClN2O
- Molgewicht:
- 332.87
- MOL-Datei:
- 135729-62-3.mol
|
Palonosetron Hydrochloride Eigenschaften
- Schmelzpunkt:
- >290°C
- alpha
- D25 -94.1° (c = 0.4 in water)
- storage temp.
- Inert atmosphere,Store in freezer, under -20°C
- Löslichkeit
- Methanol (Slightly, Heated), Water (Slightly)
- Aggregatzustand
- Solid
- Farbe
- White to Off-White
- Optische Rotation
- [α]/D -90 to -110°, c =0.4 in H2O
- Wasserlöslichkeit
- H2O: 20mg/mL, clear
- Merck
- 14,6997
- InChI
- InChI=1/C19H24N2O.ClH/c22-19-16-6-2-4-14-3-1-5-15(18(14)16)11-21(19)17-12-20-9-7-13(17)8-10-20;/h2,4,6,13,15,17H,1,3,5,7-12H2;1H/t15-,17-;/s3
- InChIKey
- OLDRWYVIKMSFFB-HYCRUXCXNA-N
- SMILES
- N1(C[C@@]2([H])CCCC3=CC=CC(=C32)C1=O)[C@H]1[C@]2([H])CCN(CC2)C1.Cl |&1:2,15,16,r|
- CAS Datenbank
- 135729-62-3(CAS DataBase Reference)
Sicherheit
- Risiko- und Sicherheitserklärung
- Gefahreninformationscode (GHS)
| WGK Germany |
WGK 3 |
|
|
| HS Code |
29339900 |
|
|
| Speicherklasse |
11 - Combustible Solids |
|
|
| Hazard Classifications |
Acute Tox. 4 Oral |
|
|
| Bildanzeige (GHS) |
|
| Alarmwort |
Warnung
|
| Gefahrenhinweise |
| Code |
Gefahrenhinweise |
Gefahrenklasse |
Abteilung |
Alarmwort |
Symbol |
P-Code |
| H302 |
Gesundheitsschädlich bei Verschlucken. |
Akute Toxizität oral |
Kategorie 4 |
Warnung |
|
P264, P270, P301+P312, P330, P501 |
| H312 |
Gesundheitsschädlich bei Hautkontakt. |
Akute Toxizität dermal |
Kategorie 4 |
Warnung |
|
P280,P302+P352, P312, P322, P363,P501 |
| H332 |
Gesundheitsschädlich bei Einatmen. |
Akute Toxizität inhalativ |
Kategorie 4 |
Warnung |
|
P261, P271, P304+P340, P312 |
|
| Sicherheit |
| P261 |
Einatmen von Staub vermeiden. |
| P264 |
Nach Gebrauch gründlich waschen. |
| P264 |
Nach Gebrauch gründlich waschen. |
| P270 |
Bei Gebrauch nicht essen, trinken oder rauchen. |
| P271 |
Nur im Freien oder in gut belüfteten Räumen verwenden. |
| P280 |
Schutzhandschuhe/Schutzkleidung/Augenschutz tragen. |
| P301+P312 |
BEI VERSCHLUCKEN: Bei Unwohlsein GIFTINFORMATIONSZENTRUM/Arzt/... (geeignete Stelle für medizinische Notfallversorgung vom Hersteller/Lieferanten anzugeben) anrufen. |
| P302+P352 |
BEI BERÜHRUNG MIT DER HAUT: Mit viel Wasser/... (Hersteller kann, falls zweckmäßig, ein Reinigungsmittel angeben oder, wenn Wasser eindeutig ungeeignet ist, ein alternatives Mittel empfehlen) waschen. |
| P304+P340 |
BEI EINATMEN: Die Person an die frische Luft bringen und für ungehinderte Atmung sorgen. |
| P312 |
Bei Unwohlsein GIFTINFORMATIONSZENTRUM/Arzt/... (geeignete Stelle für medizinische Notfallversorgung vom Hersteller/Lieferanten anzugeben) anrufen. |
| P322 |
Gezielte Maßnahmen |
| P330 |
Mund ausspülen. |
| P363 |
Kontaminierte Kleidung vor erneutem Tragen waschen. |
| P501 |
Inhalt/Behälter ... (Entsorgungsvorschriften vom Hersteller anzugeben) zuführen. |
|
Palonosetron Hydrochloride Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
Palonosetron is a novel 5-HT3 receptor antagonist launched as an injectable
agent for the prevention of acute and delayed nausea and vomiting associated with
cancer chemotherapy. It has a much longer half-life (～ 40 h) than the other currently
available 5-HT3 antagonists, which provides efficacy advantages in the prevention of
delayed nausea and vomiting that typically occurs after 24 h and up to six days post
chemotherapy administration. Palonosetron was developed as a conformationally
restricted analog of the previously known 5HT3 antagonists tropisetron and
granisetron. It is synthesized in four steps starting with the condensation of 1,8-
naphthalic anhydride and (S)-3-aminoquinuclidine to produce the corresponding
imide. The subsequent steps include catalytic hydrogenation of one of the aromatic
rings of the imide intermediate, selective reduction of one of the carbonyls to a
hydroxyl group, dehydration to an olefin and catalytic hydrogenation. The
recommended dosage of palonosteron is 0.25 mg, administered as a single
intravenous dose approximately 30 min before the start of chemotherapy. Palonosetron
exhibits dose-proportional pharmacokinetics and it is moderately bound to
plasma proteins (62%). Fifty percent of the dose is metabolized in the liver, and 40%
is excreted unchanged in the urine. In comparative clinical studies with two other 5-
HT3 receptor antagonists, palonosetron is shown to be as effective as dolasetron and
more effective than ondansetron in controlling acute nausea and vomiting and
superior to both in the control of delayed nausea and vomiting. Efficacy of palonosetron has been demonstrated in patients receiving initial and repeat courses of
both moderately and highly emetogenic chemotherapy, including cisplatin, cyclophosphamide
and dacarbazine. At 0.25 and 0.75 mg doses, palonosetron is well tolerated
and the most occurring adverse events are headache, diarrhea, fatigue, abdominal
pain and insomnia.
Chemische Eigenschaften
White Solid
Verwenden
(S,S)-Palonosetron Hydrochloride is a serotonin 5-HT3 receptor antagonist used in the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). Antiemetic.
Definition
ChEBI: A hydrochloride obtained by combining palonosetron with one molar equivalent of hydrogen chloride; an antiemetic used in combination with netupitant (under the trade name Akynzeo) to treat nausea and vomiting in patients undergoing cancer chemotherapy.
Palonosetron Hydrochloride Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
Palonosetron Hydrochloride Anbieter Lieferant Produzent Hersteller Vertrieb Händler.
Global( 564)Lieferanten
135729-62-3()Verwandte Suche:
- (S)-2-((S)-quinuclidin-3-yl)-2,3,3a,4,5
- Palonosetron hydrochloride, 99.5%, a 5-HT3 antagonist
- PALONOSETRON HYDROCHLORIDE
- CS-292
- Palonosetronhydrochloride hydrochloride
- Palonosetron-d3 HCl
- (3aS)-2-(3S)-1-Azabicyclo[2.2.2]oct-3-yl-2,3,3a,4,5,6-hexahydro-1H-benz[de]isoquinolin-1-one Hydrochloride
- Onicit
- RS-25259-197
- (3aS)-2-(3S)-1-Azabicyclo[2.2.2]oct-3-yl-2,3,3a,4,5,6-hexahydro-1H-benz[de]isoquinolin-1-one monohydrochloride
- (S,S)-Palonosetron Hydrochloride
- (S,S)-Palonosetron HCl
- (3aS)-2-[(S)-1-Azabicyclo[2.2.2]oct-3-yl]-2,3,3a,4,5,6-hexahydro-1-oxo-1H-benz[de]isoquinoline hydrochloride
- Palonosetron Hydrochloride API
- 1H-Benz[de]isoquinolin-1-one, 2-[(3S)-1-azabicyclo[2.2.2]oct-3-yl]-2,3,3a,4,5,6-hexahydro-, hydrochloride (1:1), (3aS)-
- RS 25259
- (S)-2-((S)-quinuclidin-3-yl)-2,3,3a,4,5,6-hexahydro-1H-benzo[de]isoquinolin-1-one hydrochloride
- Palonosetron hydrochloride, >=99%
- Palonosetron HCI
- PalonosetronHydrochloride>
- (S)-8-((((S)-quinuclidin-3-yl)amino)methyl)-5,6,7,8-tetrahydronaphthalene-1-carboxylic acid
- Palonosetron Hydrochloride USP/EP/BP
- a 5-HT3 antagonist
- PalnosetronHcl
- Palonosetron HCl (RS25233-197
- (5S)-3-[(3S)-1-azabicyclo[2.2.2]octan-3-yl]-3-azatricyclo[7.3.1.?,13]trideca-1(13),9,11-trien-2-one hydrochloride
- Palonosetron Hydrochloride (1492200)
- Methylisothiazolinone free base
- RS 25259 197|||Palonosetron HCl|||RS 25259
- Palonosetron Hydrochlorate
- Palonosetron hydrochloride, 10 mM in DMSO
- PALONOSETRON HYDROCHLORIDE (NON-STERILE DRUG SUBSTANCE)
- Palonosetron HCl - Bio-X ?
- (s)-2-((1r,3s,4r)-quinuclidin-3-yl)-2,3,3a,4,5,6-hexahydro-1h-benzo[de]isoquinolin-1-one hydrochloride
- PALONOSETRON HCL
- Aloxi
- 135729-62-3
- C19H24N2OHCl
- C19H25ClN2O
- C19H24N2OHC
- Selective 5-HT3 Receptor Antagonist
- Chiral Reagents
- Heterocycles
- Intermediates & Fine Chemicals
- Pharmaceuticals
- API
- 135729-62-3
